). Several BMD measurements were performed during the patient's follow-up until late puberty. RESULTS: A novel CaSR mutation (p.L123S) was identified, which, as demonstrated by functional analysis, renders CaSR more sensitive to extracellular changes of Ca 2+ compared with the WT, although the difference is not statistically significant. BMD measurements, from early childhood to late puberty, revealed high normal to elevated BMD. CONCLUSION: We present the first Greek patient, to our knowledge, with sporadic ADH due to a novel gain-of-function mutation of the CaSR gene.
INTRODUCTION
Hypocalcemia that is related to defects of the calcium sensing receptor (CaSR) and results from low parathyroid hormone (PTH) secretion is termed autosomal dominant hypocalcemia (ADH). Two types of ADH have been identified so far: ADH type 1 (ADH1) and type 2 (ADH2). The more common type is ADH1, which is the result of gain-of-function mutations of CaSR. 1 CaSR, a G protein-coupled cell surface receptor that serves as a "calciostat", is expressed in several cell types including parathyroid chief cells, calcitonin-producing thyroid C cells, bone cells and renal tubular cells. The recently recognized ADH2 is caused by germline gain-of-function mutations of GNA11 which encodes the a-subunit of G11 (Ga 11), a G-protein that transduces CaSR signaling in the parathyroid glands.
2 ADH1 is a rare familial or sporadic syndrome with clinical presentation that varies from mild asymptomatic to severe hypocalcemia and which may present in neonatal life with seizures or later with hypocalcemic symptoms such as paresthesia, carpopedal spasm or afebrile seizures. 3 Activating CaSR mutations increase the sensitivity of the receptor to extracellular calcium (Ca 2+ ), resulting in low or inappropriately normal PTH levels and reduced renal Ca 2+ reabsorption. Subsequently, affected patients develop hypocalcemia, hyperphosphatemia, hypomagnesemia and absolute or relative hypercalciuria. Patients with ADH may also present with complications due to hypercalciuria, like renal stones, nephrocalcinosis, renal impairment and basal ganglia calcifcations. 4 Regarding the bone metabolism of patients with ADH1, the possible impact of gain-of-function CaSR mutations on bone mineral density (BMD) has not been clarified.
Here we present the first patient, to our knowledge, of Greek origin with ADH1 who carries a novel mutation of the CaSR gene. We report the functional analysis of the mutation and the progression of bone mineral density from childhood through puberty.
MATERIALS AND METHODS

Case report
Our patient was a 17-day old Greek male who presented to our pediatric department with seizures. He was born at term, following an uneventful pregnancy, with normal weight, length and head circumference. He was the product of healthy unrelated parents. At presentation, biochemical investigation showed severe hypocalcemia with normal phosphate, magnesium and 1,25(OH)2D3, while PTH was at the lowest level (Table 1) . With the working diagnosis of hypoparathyroidism, calcitriol and Ca supplementation were administered; however, the hypocalcemia was difficult to correct. During the first year of life, serum Ca levels ranged from 6.8-9.1 mg/dl and spot urinary Ca ++ /Cr from 0.3-0.6 mg/mg (normal values between 7-18 months <0.6). 5 A renal ultrasound scan, performed at the age of 10 months, showed grade 1 nephrocalcinosis. The relatively high urine Ca concentration despite low serum Ca suggested that the patient had ADH. Hence, we aimed to keep serum Ca levels at around 7 mg/dl and urinary Ca within the normal range. To achieve this, the patient was also administered hydrochlorothiazide. On this treatment, serum Ca ranged from 6.8-7.6 mg/dl, 24h-urinary Ca ++ from 2.8-6 mg/kg/24h (<4) and the serum calcium x phosphate product was <55. Currently, our patient is 16 years old, with normal growth (height: 170 cm, 25 th -50 th percentile, and weight: 79.5 kg, 75 th -90 th percentile) and Tanner 5 pubertal development. He is still on calcitriol and hydrochlorothiazide; he has normal biochemistry, except for hypocalcemia, as well as normal renal function and stable grade 1 nephrocalcinosis. BMD determined at the age of 5, 7.5, 12 and 15.5 years was always increased or high-normal (z-score: +2.1, +1.45, +2.1 and +1.6, respectively). The measurements were performed in the lumbar spine (L1-L4) by dual-energy X-ray absorptiometry (DXA) with a Hologic QDR-1000 upgraded unit.
DNA studies
Genomic DNA was isolated from whole blood and exons 2-7 of the CaSR gene (NM_000388) and their respective flanking regions were PCR amplified and sequenced. Informed consent was obtained from the parents of the patient. The analysis of the CaSR gene revealed the novel heterozygous muta- ]i, upon extracellular CaCl2 addition and the baseline. All data are expressed as mean ± SEM. Statistical analysis for multiple comparisons was performed using a one-way analysis of variance (ANOVA), followed by Tukey HSD post-hoc test. Non-directional Student's t-tests were performed for comparisons involving only two groups. All statistical analyses were conducted using GraphPad Prism software. Results were considered Figure 1A , WT over-expressing cells present a threshold of [Ca 2+ ]i of 118.6 ± 5.6 nM. The cells harboring the 368T>C genetic change exhibit a trend for increased [Ca 2+ ]i (129.1 ± 11.3 nM), which however is not significant. Similarly, stimulation with exogenous addition of 3 mM CaCl2 resulted in a relatively increased Ca 2+ mobilization in the 368T>C over-expressing cells (32.80 ± 6.47 which was not statistically significant.
RESULTS
As shown in
DISCUSSION
In this study we report a novel heterozygous variant of unknown clinical significance in exon 3 of the CaSR gene in a patient with severe hypocalcemia and hypercalciuria. The alteration identified (p.L123S) was not reported in the Human Gene Mutation Database nor in reference databases (i.e. 1000 Genomes), while the functional analysis demonstrated that the altered CaSR was more sensitive to extracellular changes of Ca 2+ compared with the wild type, although the difference was not significant. Furthermore, according to the prediction tools PolyPhen and SIFT, this mutation is characterized as probably damaging (score: 0.990) or tolerated (score: 0.460), respectively. The p.L123S genetic change is localized in the extracellular domain of the receptor which is essential for ligand binding. It has been suggested that mutations in this region affect the three-dimensional structure of the receptor, resulting in a "more sensitive" conformational state. 7 This finding is also supported by a previous mutagenesis study showing that mutations localized between amino acids 116 and 136 in the CaSR protein lead to increased basal activity of the receptor as well as increased affinity for Ca 2+ . 8 However, some mutations seem to result in mild asymptomatic hypocalcemia, despite the localization of the alterations in critical protein regions, while other mutations, located in the same protein region, have different effects on the receptor's activity. 7 Our patient presented with severe hypocalcemia and seizures in the neonatal period that did not correlate with the degree of his CaSR sensitivity to changes of exogenous Ca 2+ concentrations.
Interestingly, our proband also had mildly increased BMD despite chronic hypocalcemia. This could be attributed to chronic hypoparathyroidism, which is characterized by reduced bone remodeling and increased bone mass. 9 Patients with ADH present PTH levels in the low normal or slightly below the normal range in contrast to patients with hypoparathyroidism, who have very low to undetectable PTH levels. Due to the rarity of this disorder in childhood, studies on the bone mineral density of children with hypoparathyroidism are scarce. In a NIH cohort of more than 30 hypoparathyroid children, bone mineral density was not increased. 10 Although little is known about the effects of CaSR mutations on bone metabolism, it has been shown that CaSR is expressed in bone cells, while in vitro studies have identified anabolic effects of overactive CaSR in bone by its promotion of osteoblast differentiation and inhibition of osteoclastogenesis. However, the data from in vivo studies, which are controversial, suggest that CaSR activation leads to enhanced bone resorption and mild osteopenia, although similar implications in humans have not been demonstrated as yet. 11 From the very few studies examining the BMD of patients with ADH, it seems that patients with different activating CaSR mutations may present with low, normal or high BMD. [12] [13] [14] [15] It is interesting to note that our patient, as well as the three patients with increased BMD previously reported, 12 all harbored mutations within the same region of the extracellular domain of the receptor. The possible correlation between BMD and specific mutations, especially if also including bone histomorphometry data, would add further knowledge regarding the effects of activating CaSR mutations on human bone density and metabolism.
In conclusion, we present, to the best of our knowledge, the first patient of Greek origin who carries a novel genetic alteration of the CaSR gene while presenting with severe neonatal hypocalcemia. More studies on the effect of CaSR mutations on BMD are needed.
